As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Press releases

Enalees announces clinical trial for a COVID-19 test

16 September 2020
C4Diagnostics, Bertin Technologies and Enalees announced the launch of a prospective clinical trial for BEC-SARS-CoV-2 for humans, a rapid, point-of-care diagnostic for COVID-19.
Covid illustration CP Covid illustration CP
  • The trial has received ethics committee approval
  • It is now underway in several French healthcare centers
  • CE-IVD marking is expected for the end of September 2020

C4Diagnostics, Bertin Technologies and Enalees have launched a prospective clinical trial for BEC-SARS-CoV-2 for humans, a test developed in partnership with Institut Pasteur to detect the etiological agent of COVID-19.

BEC-SARS-CoV-2 for humans was submitted as required to French regulatory authorities, the detection process was validated and the clinical trial was launched by the partners with the objective of obtaining CE-IVD marking by the end of September.

Currently, the test is available for research use only. The sensitive, rapid and portable test employs reverse transcription loop-mediated isothermal amplification (RT-LAMP), a combination of two innovative technologies to extract and detect viral RNA.

The diagnostic provides results for COVID-19 detection within the 25 minutes following a nasal or nasopharyngeal swab. It comprises an internal control and two targets (in conformity with WHO and HAS recommendations).

Laurent Thiery, Enalees CEO and Co-founder:
BEC-SARS-CoV-2 for humans is built upon an Enalees concept that, for two years now, has enabled the in-the-filed detection and treatment of respiratory diseases in horses and other domesticated animals. More precisely, the foundation of this new diagnostic is our technology for the rapid extraction of viral RNA, which has already been clinically validated in veterinary medicine. The test also calls upon an RT-LAMP–based rapid molecular diagnostics technology used not only by Enalees, but also by the Institut Pasteur during past health crises such as the Ebola and Zika epidemics. We were able to adapt our standardized and optimized protocols for sample preparation and analysis to human SARS-CoV-2 in a timeframe compatible with the management of the current health crisis. BEC-SARS-CoV-2 for humans offers a solution with demonstrated performance and ease of use. This integrated methodology shines a light on the One Health approach, which associates the best of public, animal and environmental health.

Younes Lazrak, CEO of C4Diagnostics:
While awaiting the development of an efficacious vaccine, France needs to increase its capacities in and deployment of testing. We are contributing to the management of the COVID-19 crisis with our diagnostic test, which is particularly pertinent when lab access is difficult or even impossible (when at sea for example) and/or immediate results are needed to test asymptomatic but potentially infected people there where they are. This capacity for testing individuals potentially exposed to COVID-19 on-site and in a matter of minutes is a major breakthrough for accessible screening (in air or rail travel, for example).  Our early results are being consolidated today in a prospective, multicenter clinical trial headed by the Institut Pasteur.  The trial will measure the specificity and sensitivity of our BEC-SARS-CoV-2 for humans diagnostic test, which we hope to have CE-certified by September. It will further strengthen the range of solutions that C4Diagnostics has been proposing in the fight against COVID-19 since the pandemic began.”

Bruno Vallayer, General Director of Bertin Technologies:
As do the vast majority of products developed by Bertin Technologies, this French developed and manufactured test meets the most demanding quality standards. BEC-SARS-CoV-2 for humans is complementary to the test we developed and commercialized jointly in May of 2020: BEC-SARS-CoV-2 for the environment. This latter, teamed with the Coriolis biological air sampler, provides a complete solution for environmental contamination analyses. Used as a duo, the two BEC-SARS-CoV-2 tests provide COVID-19 screening both for the environment and for the family, friends and coworkers of an infected person. This two-pronged approach is essential for managing epidemic hotspots in a controlled and localized manner.”


    BEC-SARS-CoV-2 for humans employs RT-LAMP technology, which provides a sensitivity for SARS-CoV-2 RNA detection equivalent to that of RT-PCR. RT-LAMP is an amplification method that, unlike conventional RT-PCR, does not require thermal cycling to amplify RNA. Its advantages include rapidity, simplicity and robustness. Among the current isothermal amplification methods, LAMP has been garnering significant attention over the last few years. For example, the World Health Organization recommended its use for diagnosing tuberculosis.

    BEC-SARS-CoV-2 for humans meets the French National Authority for Health’s recommendations for robustness and performance. It comprises two viral targets to improve specificity and an endogenous positive control to confirm sampling quality and device & test function, thus limiting false negatives.


    An affiliate of the CNIM Group, Bertin Technologies builds upon its vast experience in innovation to develop, produce and market groundbreaking systems and instruments across the globe. Its activity in instruments is represented by the Bertin Instruments brand. Bertin Technologies’ innovative measuring and sampling solutions respond to the demanding needs of particular markets:

    • life sciences (biological air sampler, biological sample preparations, bioanalysis kits, digital microscopy);
    • nuclear and radioprotection (portable radioprotection equipment, environmental radiation monitoring, radiation portal monitors, radon professional monitoring);
    • defense, security and safety: critical sites, forces and infrastructures protection (CBRN threat detection, optronic surveillance modules, unattended ground sensor platform with its affiliate Exensor).


    Based in Marseille, France, C4Diagnostics conceives, develops and commercializes in vitro diagnostic tests for infectious diseases. Laureates of numerous prizes, the company’s tests are based on a state of the art technology that enables the detection of pathogenic microorganisms via their own metabolism. With its disruptive technologies, C4Diagnostics aims to become a world leader in in vitro infectious diseases diagnostics by furnishing appropriate, more sensitive information to physicians and patients with greater rapidity. C4Diagnostics addresses key issues in public health, such as infection control and antibiotic resistance.

    Since April 2020, the company has been operating the SARS-CoV-2 testing platform COMETE (COVID-19 Environmental Testing) for the Marseille Navy Firefighters Battalion.


    Enalees is a French company created in 2015 and located at Genopole, in the city of Évry, just south of Paris.

    Enalees develops, produces and markets molecular diagnostics kits for infectious diseases such as equine influenza, leptospirosis or Lyme disease in domesticated animals (horses, dogs and cats). The company thus provides veterinarians with innovative, simple, rapid, point-of-care tests. Its first tests for detecting infectious diseases in horses were launched in 2019 and are already being used in a fourth of France’s equine clinics. The recent commercialization of tests for dogs and cats has brought the Enalees catalog up to 15 products, available currently in Europe and soon in North America.



Laurent THIERY, PhD CEO  et co-founder
+33 6 32 512 519

Bertin Technologies

Agence Gootenberg Frédérique Vigezzi
+33 6 10 82 64 30

Laurence Colin
+33 6 82 80 16 43

Charlotte Riquier, Marketing Manager – BERTIN +33 6 07 42 16 53


Thomas Tran, VP Sales & Marketing EMEA
+33 6 10 69 83 86

Ophélie Philipot, Press Officer
+33 6 70 07 87 47

Article posted on 16 September 2020

With the support from
Région île de France